Implant breast reconstruction followed by radiotherapy: can helical tomotherapy become a standard irradiation treatment?

• Published in: Medical dosimetry : official journal of the American Association of Medical Dosimetrists Vol. 37; no. 4; p. 425
• Main Authors: Massabeau, Carole, Fournier-Bidoz, Nathalie, Wakil, Georges, Castro Pena, Pablo, Viard, Romain, Zefkili, Sofia, Reyal, Fabien, Campana, François, Fourquet, Alain, Kirova, Youlia M
• Format: Journal Article
• Language: English
• Published: United States 2012
• Subjects: Breast Implants; Breast Neoplasms - therapy; Combined Modality Therapy; Female; Humans; Mammaplasty - instrumentation; Mammaplasty - methods; Radiometry - methods; Radiotherapy Dosage; Radiotherapy Planning, Computer-Assisted - methods; Radiotherapy, Adjuvant - methods; Radiotherapy, Intensity-Modulated - methods; Treatment Outcome
• ISSN: 1873-4022
• DOI: 10.1016/j.meddos.2012.03.006

To evaluate the benefits and limitations of helical tomotherapy (HT) for loco-regional irradiation of patients after a mastectomy and immediate implant-based reconstruction. Ten breast cancer patients with retropectoral implants were randomly selected for this comparative study. Planning target volumes (PTVs) 1 (the volume between the skin and the implant, plus margin) and 2 (supraclavicular, infraclavicular, and internal mammary nodes, plus margin) were 50 Gy in 25 fractions using a standard technique and HT. The extracted dosimetric data were compared using a 2-tailed Wilcoxon matched-pair signed-rank test. Doses for PTV1 and PTV2 were significantly higher with HT (V95 of 98.91 and 97.91%, respectively) compared with the standard technique (77.46 and 72.91%, respectively). Similarly, the indexes of homogeneity were significantly greater with HT (p = 0.002). HT reduced ipsilateral lung volume that received ≥20 Gy (16.7 vs. 35%), and bilateral lungs (p = 0.01) and neighboring organs received doses that remained well below tolerance levels. The heart volume, which received 25 Gy, was negligible with both techniques. HT can achieve full target coverage while decreasing high doses to the heart and ipsilateral lung. However, the low doses to normal tissue volumes need to be reduced in future studies.